Aurobindo Pharma announced that the companys Unit XI, an API Non-antibiotic manufacturing facility situated at Pydibhimavaram, Srikakulam District, Andhra Pradesh was inspected by the United States Food and Drug Administration (USFDA) in February 2019 and issued a warning letter in June 2019 and this Unit was further inspected by USFDA from 25 July to 2 August 2022 and issued a Form 483 with 3 observations. Subsequent to the companys responses for the aforesaid observations, the company has received an Establishment Inspection Report (EIR) classifying the inspection as Voluntary Action Indicated (VAI) from the US FDA and with this, the inspection at the Unit XI is concluded. Powered by Capital Market – Live News
Related Tags
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
